Cadaveric renal transplantation in hepatitis B antigen–positive recipients using hepatitis B antigen–positive donor organs with lamivudine treatment

Kim, J.A; Huh, Wooseong; Lee, K.W; Kim, S.J; Kim, Y.-G; Kim, D.J; Joh, Jae‐Won; Oh, Hayoung

doi:10.1016/j.transproceed.2004.05.014

Cited by 9 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies investigating use of HBsAg-positive kidney donors have shown that the policy of transplanting such kidneys to HBsAg-positive recipients with natural immunity is reasonable and seems to be safe [ 48 – 52 ].…”

Section: Kidney Transplantations From Hbsag-positive Donorsmentioning

confidence: 99%

Kidney Transplantation From Donors with Hepatitis B

et al. 2016

View full text Add to dashboard Cite

The growing demand for organ donors to supply the increasing number of patients on kidney waiting lists has led most transplant centers to develop protocols that allow safe use of organs from donors with special clinical situations previously regarded as contraindications. Deceased donors with previous hepatitis B may be a safe resource to increase the donor pool even if there is still controversy among transplantation centers regarding the use of hepatitis B surface antigen-positive donors for renal transplantation. However, when allocated to serology-matched recipients, kidney transplantation from donors with hepatitis B may result in excellent short-term outcome. Many concerns may arise in the long-term outcome, and studies must address the evaluation of the progression of liver disease and the rate of reactivation of liver disease in the recipients. Accurate selection and matching of both donor and recipient and correct post-transplant management are needed to achieve satisfactory long-term outcomes.

show abstract

Section: Kidney Transplantations From Hbsag-positive Donorsmentioning

confidence: 99%

Kidney Transplantation From Donors with Hepatitis B

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The remaining 4 patients had normal kidney and liver functions in follow‐up. The authors emphasized the importance of close follow‐up in this group of patients . In our study, in recipients whose donors were HBsAg(+), no acute hepatitis, liver failure, or graft or patient loss was observed.…”

Section: Discussionmentioning

confidence: 54%

“…It is believed that organ transplantation from HBsAg(+) donors can lead to liver complications and acute exacerbations of hepatitis owing to the transferred viral load, and that these complications have negative impacts on graft function, and graft and patient survival. In one study of the outcomes of HBsAg(+) recipients who underwent RTx from HBsAg(+) donors, 1 of the recipients was lost because of liver complications, 1 patient developed graft loss caused by acute rejection, and the remaining 4 recipients had good graft function without any complications at follow‐up .…”

mentioning

confidence: 99%

Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(−) donors

Yılmaz

Aliosmanoglu

Erbiş

et al. 2016

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Another interesting issue is the use of HBsAg positive donors to recipients with HBsAg positive serology. A few studies[ 63 - 66 ] have reported favorable outcomes of this treatment option provided that the recipients received antiviral treatment before transplantation. Also, there is a suggestion that the recipients with positive HBsAg should have the result of liver biopsy that did not show evidence of cirrhosis.…”

Section: The Role Of Prophylaxis Therapymentioning

confidence: 99%

Kidney transplant from donors with hepatitis B: A challenging treatment option

Srisuwarn

Sumethkul

2021

WJH

View full text Add to dashboard Cite

Utilizing kidneys from donors with hepatitis B is one way to alleviate the current organ shortage situation. However, the risk of hepatitis B virus (HBV) transmission remains a challenge that undermines the chance of organs being used. This is particularly true with hepatitis B surface antigen (HBsAg) positive donors despite the comparable long-term outcomes when compared with standard donors. To reduce the risk of HBV transmission, a comprehensive approach is needed. This includes assessment of donor risk, optimal allocation to the proper recipient, appropriate immunosuppressive regimen, optimizing the prophylactic therapy, and post-transplant monitoring. This review provides an overview of current evidence of kidney transplants from donors with HBsAg positivity and outlines the challenge of this treatment. The topics include donor risk assessment by adopting the nucleic acid test coupled with HBV DNA as the HBV screening, optimal recipient selection, importance of hepatitis B immunity, role of nucleos(t)ide analogues, and hepatitis B immunoglobulin. A summary of reported long-term outcomes after kidney transplantation and proposed criteria to utilize kidneys from this group of donors was also defined and discussed.

show abstract

Cadaveric renal transplantation in hepatitis B antigen–positive recipients using hepatitis B antigen–positive donor organs with lamivudine treatment

Cited by 9 publications

References 19 publications

Kidney Transplantation From Donors with Hepatitis B

Kidney Transplantation From Donors with Hepatitis B

Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(−) donors

Kidney transplant from donors with hepatitis B: A challenging treatment option

Contact Info

Product

Resources

About